Invesco
FHTX icon

Invesco’s Foghorn Therapeutics FHTX Stock Holding History

Invesco’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$84.8K Buy
17,736
+6,951
+64% +$38.2K ﹤0.01% 3644
2025
Q4 		$58.2K Buy
+10,785
New +$48.9K ﹤0.01% 3691
2024
Q2 		– Sell
-56,042
Closed -$376K – 3915
2024
Q1 		$376K Buy
+56,042
New +$311K ﹤0.01% 3452

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Invesco's FHTX Position: Q1 2026 in Review

Invesco increased its Foghorn Therapeutics (FHTX) stake by 64% in Q1 2026, buying an estimated $38.2K and bringing the position to 17,736 shares worth $84.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3644.

Invesco first reported a position in FHTX in Q1 2024 and has held it in 3 quarters since. The position peaked at $376K in Q1 2024. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Invesco held 17,736 shares of Foghorn Therapeutics worth $84.8K as of Q1 2026.
  • Invesco bought 6,951 Foghorn Therapeutics shares in Q1 2026, an estimated $38.2K.
  • Foghorn Therapeutics made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #3644 holding.
  • Invesco first reported a position in Foghorn Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Invesco's Foghorn Therapeutics position peaked at $376K in Q1 2024.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.